← Russell 3000 cross-section

TEM Tempus AI, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-07-30, not restated
Technology

Scale

Market cap
$12.4bn
Revenue TTM
$1.4bn
Net income TTM
$-254m
Free cash flow
$-263m
Composite score
Sector rank
#623

Valuation

P / E
EV / EBITDA
EV / sales
8.2
FCF yield
-2.12%
Earnings yield vs 10-yr
-6.78pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-17.8%
EBITDA margin
-17.6%
ROE
-57.2%
ROIC
Revenue growth

Insider activity, last 90 days

Net open-market
$-58.05m
Buyers
0
Sellers
9

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

We primarily operate in the United States and generated total revenue of $382.5 million and $314.6 million in the three months ended June 30, 2026 and 2025, respectively, and $730.6 million and $570.4 million in the six months ended June 30, 2026 and 2025, respectively. Components of Results of Operations Revenue We currently primarily derive our revenue from our two product lines: (1) Diagnostics and (2) Data and applications. Diagnostics Diagnostics primarily includes revenue from Oncology testing (legacy Tempus) and Hereditary testing (legacy Ambry Genetics). …Tempus AI, Inc., 10-Q, period ended 2026-06-30, filed 2026-07-30

Read the full passage →